Skip to content

Effectiveness of an Online Intervention Targeting Cancer-related Fatigue

Effectiveness of a Newly Developed Online Intervention on Alleviating Cancer-Related Fatigue in Patients and Survivors

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03809130
Enrollment
27
Registered
2019-01-18
Start date
2018-12-10
Completion date
2019-06-20
Last updated
2020-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Survivor, Malignant Neoplasm

Brief summary

This trial studies how well Untire application intervention works in reducing cancer-related fatigue in cancer patients and survivors.The Untire application focuses on themes that have been identified as causing or contributing to cancer-related fatigue. It may provide information and tips to improve lifestyle, give exercises for body and mind to increase energy levels, offer weekly reports to measure progress, and offer access to an online support community.

Detailed description

PRIMARY OBJECTIVES: I. To assess the effectiveness of an online multidisciplinary psychological training program delivered via a smartphone-based application (the Untire app) in reducing patient-reported fatigue in cancer patients and survivors. SECONDARY OBJECTIVES: I. To determine the dose-response association between use of the Untire app and reduction in patient-reported fatigue severity. II. To explore whether changes in positive and negative affect, depressive symptoms interact with the effects of the Untire app on fatigue severity. III. To explore the predictive value of genetic markers (single-nucleotide polymorphisms) and personality characteristics for effectiveness of the Untire app in reducing patient-reported fatigue. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients use Untire application intervention after baseline up to 6 months. ARM II: Patients use Untire application intervention after 3 months up to 6 months.

Interventions

OTHERInternet-Based Intervention

Use Untire application after baseline up to 6 months

OTHERQuality-of-Life Assessment

Ancillary studies

OTHERQuestionnaire Administration

Ancillary studies

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who present at the Cancer-Related Fatigue Clinic or the Psychiatric Oncology Clinic for an initial consult * Patients who speak and read English * Patients who are willing and able to review, understand, and provide written consent * Patients who agree to comply with all study procedures * Patients who are in possession of a smartphone or tablet that supports the Untire app software * Patients rating their current fatigue severity as moderate to severe (= or \> 4 on a 0-10 scale), assessed as part of the clinics' screening procedure

Exclusion criteria

* Case report of diagnosis of a formal thought disorder (e.g., schizophrenia)

Design outcomes

Primary

MeasureTime frameDescription
Change in patient-reported fatigue severity as assessed with the Checklist Individual Strength (CIS) between T0 and T1Baseline up to 3 monthsThe effect of the intervention on fatigue will be analyzed with a generalized linear model, including CIS-20 sum score at T1 as the dependent variable, CIS-20 sum score at T0 as covariate, and group (intervention versus wait-list control) as independent variable.

Secondary

MeasureTime frameDescription
Total number of activities completed on the appUp to 6 monthsChange in fatigue between T0 and T1 for the intervention group and between T1 and T2 for the wait-list control group will be entered as dependent variable in multiple regression models, with group allocation as covariate. Separate models will be computed including the different app-usage metrics assessed between T0 -T1 for the intervention group and T1-T2 for the control group as independent variable. These models will additionally be calculated for change in fatigue and use of the app between T0 and T2, for patients in the intervention arm only.
Total number of completed assessments on the appUp to 6 monthsChange in fatigue between T0 and T1 for the intervention group and between T1 and T2 for the wait-list control group will be entered as dependent variable in multiple regression models, with group allocation as covariate. Separate models will be computed including the different app-usage metrics assessed between T0 -T1 for the intervention group and T1-T2 for the control group as independent variable. These models will additionally be calculated for change in fatigue and use of the app between T0 and T2, for patients in the intervention arm only.
Change in negative affect (delta-NA) between T0-T1Baseline up to 3 monthsThe linear model described for the primary objective will be repeated.
Total days on which the patient logged in to the appUp to 6 monthsChange in fatigue between T0 and T1 for the intervention group and between T1 and T2 for the wait-list control group will be entered as dependent variable in multiple regression models, with group allocation as covariate. Separate models will be computed including the different app-usage metrics assessed between T0 -T1 for the intervention group and T1-T2 for the control group as independent variable. These models will additionally be calculated for change in fatigue and use of the app between T0 and T2, for patients in the intervention arm only.
Change in depressive symptoms (delta-depr) between T0 and T1Baseline up to 3 monthsThe linear model described for the primary objective will be repeated.
Personality traitsUp to 6 monthsPersonality traits and their interaction with group will be added as independent variables to the linear model described for the primary objective.
GenotypesUp to 6 monthsGenotypes will be dichotomized (presence of minority alleles in the gene of interest) and added as covariates and in interaction with group to the models.
Change in positive affect (delta (PA) between T0-T1Baseline up to 3 monthsThe linear model described for the primary objective will be repeated.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026